Antibody Production
End-to-end antibody-drug conjugate development covering conjugation process optimisation, payload screening and quality assessment for precision medicine programmes.
End-to-end antibody-drug conjugate (ADC) development covering conjugation process optimisation, payload screening and quality assessment for precision medicine programmes.
The ADC platform sits within SanjingBio's target-to-PCC integrated R&D system alongside the in vitro/in vivo efficacy and drug characterisation platforms, so conjugates move straight into cell-based efficacy assays, animal efficacy screening and multi-dimensional characterisation.
Upstream it connects to antibody discovery, humanization and affinity maturation, and recombinant production — antibody molecule through conjugate on a single chain.
Enquire now →
Three stages covering the full ADC development workflow; the plan is customised to the molecule and project stage.
The conjugation reaction is optimised to the antibody and linker chemistry
Payload combinations are screened and the conjugates assessed
The conjugate undergoes systematic quality assessment with a delivered report
The ADC platform sits inside SanjingBio's target-to-PCC integrated R&D system alongside the in vitro/in vivo efficacy and drug characterisation platforms — conjugates can move straight into cell-based efficacy assays, animal efficacy screening and multi-dimensional characterisation.
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
